Cargando…

Multiple Sclerosis Relapses Following Cessation of Fingolimod

BACKGROUND: There is growing interest in the issue of disease reactivation in multiple sclerosis following fingolimod cessation. Relatively little is known about modifiers of the risk of post-cessation relapse, including the delay to commencement of new therapy and prior disease activity. OBJECTIVE:...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malpas, Charles B., Roos, Izanne, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989797/ https://www.ncbi.nlm.nih.gov/pubmed/35303292 http://dx.doi.org/10.1007/s40261-022-01129-7

Ejemplares similares

Observational studies of treatment effectiveness in neurology
por: Kalincik, Tomas, et al.
Publicado: (2023)

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom
por: Spelman, Timothy, et al.
Publicado: (2021)

Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis
por: Uher, Tomas, et al.
Publicado: (2021)

The MSBase pregnancy, neonatal outcomes, and women’s health registry
por: Jokubaitis, Vilija G., et al.
Publicado: (2021)

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
por: Lefort, M., et al.
Publicado: (2022)

Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic
por: Li, Vivien, et al.
Publicado: (2022)

Confirmed disability progression as a marker of permanent disability in multiple sclerosis
por: Sharmin, Sifat, et al.
Publicado: (2022)

Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)
por: Maltby, Vicki E, et al.
Publicado: (2021)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy
por: Lizak, Nathaniel, et al.
Publicado: (2020)

Cognitive clinico‐radiological paradox in early stages of multiple sclerosis
por: Uher, Tomas, et al.
Publicado: (2017)

Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study
por: Seery, Nabil, et al.
Publicado: (2021)

Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry
por: Spelman, Tim, et al.
Publicado: (2022)

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
por: Sharmin, Sifat, et al.
Publicado: (2023)

Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study
por: Kalincik, Tomas, et al.
Publicado: (2012)

Monitoring of radiologic disease activity by serum neurofilaments in MS
por: Uher, Tomas, et al.
Publicado: (2020)

Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2023)

Comparison of first-line and second-line use of fingolimod in relapsing MS: The open-label EARLIMS study
por: Fernández, Oscar, et al.
Publicado: (2020)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Continuing fingolimod after development of macular edema: A case report
por: Li, Vivien, et al.
Publicado: (2014)

Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis
por: Sato, Kazunori, et al.
Publicado: (2018)

Fulminant MS Reactivation Following Combined Fingolimod Cessation and Yellow Fever Vaccination
por: Rolfes, Leoni, et al.
Publicado: (2019)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Effectiveness, safety and health-related quality of life of multiple sclerosis patients treated with fingolimod: results from a 12-month, real-world, observational PERFORMS study in the Middle East
por: Achiron, Anat, et al.
Publicado: (2017)

Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis
por: Daruwalla, Cyrus, et al.
Publicado: (2023)

Efficacy of botulinum toxin type a in the targeted treatment of sleep bruxism: a double-blind, randomised, placebo-controlled, cross-over study
por: Cruse, Belinda, et al.
Publicado: (2022)

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure
por: Geissbühler, Yvonne, et al.
Publicado: (2018)

Fingolimod in children with Rett syndrome: the FINGORETT study
por: Naegelin, Yvonne, et al.
Publicado: (2021)

Sensory-Neural Hearing Loss as an Early Rebound Relapse after Fingolimod Cessation in Multiple Sclerosis
por: Naser Moghadasi, Abdoreza, et al.
Publicado: (2020)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Predictors of disability worsening in clinically isolated syndrome
por: Jokubaitis, Vilija G, et al.
Publicado: (2015)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
por: Cohen, Jeffrey A., et al.
Publicado: (2019)

Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry
por: Butzkueven, Helmut, et al.
Publicado: (2021)

What Do Effective Treatments for Multiple Sclerosis Tell Us about the Molecular Mechanisms Involved in Pathogenesis?
por: Buzzard, Katherine A., et al.
Publicado: (2012)

Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases
por: Schmidt, Stephan, et al.
Publicado: (2019)

Progressive multifocal leukoencephalopathy or immune reconstitution inflammatory syndrome after fingolimod cessation? A case report
por: Mickeviciene, D., et al.
Publicado: (2022)

Determination of Seminal Concentration of Fingolimod and Fingolimod‐Phosphate in Multiple Sclerosis Patients Receiving Chronic Treatment With Fingolimod
por: David, Olivier J., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_58vt1lrerjf9k49d4g2f0gm7gn